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ABSTRACT 
 
Comparison of Post-licensure safety surveillance of 13-Valent Pneumococcal 
Conjugate vaccine and 7-Valent Pneumococcal Conjugate vaccine: Data from the 
Vaccine Adverse Event Reporting System (VAERS). 
 
Background: On February 24, 2010, Food and Drug Administration (FDA) licensed a 
13-valent pneumococcal conjugate vaccine (Prevnar 13®, [PCV13]) for use among 
children aged 6 weeks--71 months. The Advisory Committee on Immunization Practices 
(ACIP) recommended PCV13 routine vaccination of all children aged 2--59 months, 
children aged 60--71 months with underlying medical conditions, with PCV13 replacing 
PCV7 for all doses.  
 
Methods: We searched case reports to the Vaccine Adverse Event Reporting System 
(VAERS), a US passive surveillance system, for adverse events (AEs) reported after 
immunization with PCV13 vaccine from February 24, 2010 through February 24, 2011 
for persons vaccinated from February 24, 2010 through December 31, 2010 and 
compared them with AEs reported by persons who were vaccinated with PCV7. 
 
Results: VAERS received 1503 reports of AEs after PCV13; multiple vaccines were 
given in 79.0% of reports. One hundred eighty (11.9%) were coded as serious, including 
nineteen reports of death. The most frequently reported symptoms were injection site 
reactions, fever, irritability and vomiting. Seven hundred fifty-eight (50.4%) reports 
comprised males. Most reports (37.7%) were from children 1-2 years. Total number of 
reports received for PCV13 was very similar to those received after vaccination with 
PCV7.  
Conclusions: AEs reported to VAERS following 13-valent pneumococcal conjugate 
vaccine were consistent with AEs previously observed in pre-licensure trials. We did not 
identify any major safety concerns or outcomes. 
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CHAPTER I 
 
INTRODUCTION 
 
Streptococcus pneumoniae (pneumococcus) is a lancet-shaped, gram-positive, facultative 
anaerobic bacteria first isolated by Pasteur in 1881. Pneumococcus is a common leading 
cause of bacteremia, meningitis and community acquired pneumonia among all ages, it is 
also a major cause of sinusitis and acute otitis media. Across Europe and North America, 
30-100 cases of pneumonia per 100,000 people are expected each year (Heymann, 2008). 
The highest rates of invasive pneumococcal disease (IPD) occur among young children, 
especially those younger than 2 years of age; Bacteremic pneumonia accounts for 12%–
16% of IPD. In the United States (U.S) Pneumococcus has become the leading cause of 
bacterial meningitis among children younger than 5 years of age and is a common cause 
of acute otitis media; by age 12 months, more than 60% of children have had at least one 
episode of acute otitis media (Atkinson et al., 2009).   
 
On February 2000 the Food and Drug Administration (FDA) approved a 7-valent 
pneumococcal conjugate vaccine (Prevnar®, PCV7), the first pneumococcal conjugate 
vaccine licensed in the U.S to prevent invasive pneumococcal disease. In 2002, two years 
after licensure, PCV7 was also indicated and approved for active immunization of infants 
against otitis media caused by vaccine serotypes. Prior to licensure randomized clinical 
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trials were conducted in infants and children; good vaccine efficacy and a favorable 
safety profile were demonstrated (MMWR; December 10, 2010 / 59(RR11); 1-18). 
Prior to the introduction of PCV7, in children younger than 2 years the incidence of 
invasive pneumococcal disease was 166.9 per 100000 child years in the U.S (Robinson K 
et al., 2001). New conjugate vaccines may be able to prevent and reduce the burden of 
invasive pneumococcal disease as well as reducing the incidence rates of acute otitis 
media in young children 
 
The World Health Organization (WHO) in 2007 recommended all countries to include 
pneumococcal conjugated vaccines to their national infant immunization programs 
(WHO position paper, 2007). 
 
On February 24, 2010, the FDA licensed a 13-valent pneumococcal conjugate vaccine 
(Prevnar 13®, PCV 13), for prevention of IPD caused by the 13 pneumococcal serotypes 
covered by the vaccine and for prevention of otitis media caused by serotypes in the 7-
valent pneumococcal conjugate vaccine formulation (Prevnar®, PCV7) (FDA Product 
approval information–CBER, 2010).   
 
PCV13 is made by Pfizer Inc., the manufacturer of PCV7. The formulation and 
manufacturing process for the PCV13 vaccine was the same as that used for PCV7 
vaccine,  and the safety profile of licensed PCV13 was anticipated to be similar to that of 
PCV7, which has an excellent safety record. 
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The Advisory Committee on Immunization Practices (ACIP) recommended PCV13 for 
routine vaccination of all children aged 2-59 months, children aged 60-71 months with 
underlying medical conditions that increase their risk for pneumococcal disease or 
complications and children who previously received 1 or more doses of PCV7.  PCV13 
was slated to be a successor to PCV7 (MMWR; December 10, 2010 / 59(RR11);1-18). 
 
An important factor to assess during pre-licensure is the detail evaluation of vaccine 
safety. For PCV7 and PCV13 no major safety problems were identified, however it is 
impossible to identify all safety concerns during clinical trials and there is always a 
possibility of not detecting some unusual adverse events.  Clinical trials and post-
licensure safety surveillance are critical to maintaining public health and trust in the 
Pneumococcal 13-valent Conjugate Vaccine. Due to the increased number of subjects 
exposed to the product after licensure investigators must continue to monitor, evaluate 
and characterize the potential adverse events of the product. This will allow for detection 
of unexpected adverse events and establish product’s safety profile thus help for decision 
making.   
 
Being able to distinguish events that could be potentially related to a vaccine and those 
that occur coincidentally is crucial. The quick identification and characterization of any 
adverse reactions to the vaccine can help distinguish between causal and no causal 
events.  
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This investigation will focus on and summarize the potential adverse events following 
immunization with PCV13 reported to the Vaccine Adverse Event Reporting System 
(VAERS), a national passive surveillance system and primary method to detect vaccine 
safety signals. Frequencies of adverse events occurring following immunization with 
PCV13 and adverse events previously reported with PCV7 will be compared, taking into 
account possible bias, confounding, and probable associations. Although causality 
between vaccines and adverse events is not assessed by VAERS, it can detect signals, 
unusual or unexpected product-event combinations for more rigorous investigation using 
more appropriate epidemiological study designs (Zhou W, et al. 2003). 
 
This examination uses data from a passive surveillance system that has important 
limitations and is subject of to both underreporting and over reporting, particularly in the 
first year after introduction of a new product (Rosenthal S, et al., 1995). Despite the 
limitations, VAERS has played an important role in monitoring adverse events following 
immunization.  Its ability to detect adverse signals, for example, was demonstrated by 
uncovering an association between Rotavirus vaccine (Rotashield®) and Intussusception 
(MMWR February 6, 2009 / 58(RR02);1-25). Due to these limitations causality cannot be 
determined; other epidemiologic studies must be used for confirmation.  
 
1.1 Background 
 
During pre-licensure randomized clinical trials assessed the safety of both Pneumococcal 
conjugated vaccines PCV7 and PCV13, showing favorable results in about 19,000 young 
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children who received PCV7 and approximate 5,000 infants who received PCV13 (FDA. 
Product approval information–CBER, 2010).   At introduction, PCV13 is indicated for 
active immunization for the prevention of invasive disease caused by S. pneumoniae 
serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. PCV13 is also indicated 
for the prevention of otitis media caused by S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 
19F, and 23F. No otitis media efficacy data are available for serotypes 1, 3, 5, 6A, 7F, 
and 19A (FDA, product approval information –CBER, 2010). 
 
In the post-licensure period, a similar safety favorable results was provided for the first 
two years of PCV7 when comparing PCV7 to other vaccines after an estimated 
distribution of 31.5 million doses of PCV7 within the U.S. Adverse events described in 
children younger than 18 years old vaccinated with PCV7 were minor and similar to 
those observed in pre-licensure trails (Robert P. Wise et al., 2004). In 2008 a systematic 
review of 42 studies regarding the pre-and post-licensure safety profile of pneumococcal 
conjugate vaccines did not identify major safety issues with pneumococcal vaccines 
(Frank DeStefano et al., 2008). Although some hospitalizations were caused by reactive 
airway disease seen in PCV7 and 9-Valent Pneumococcal Conjugate vaccine recipients 
compared to controls (Black S et al., 2000 and Klugman et al., 2003) the outcome of 
extensive studies in the U.S. did not corroborate such an association (FDA. Product 
approval information–CBER, 2010). 
 
The safety profile of PCV13 was assessed in 13 clinical trials; Approximately 15,000 
doses were given to 5,000 healthy infants 6 weeks through 15 months of age and the 
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comparison group of 2,760 children received at least 1 dose of PCV7.  The most 
commonly reported adverse reactions (≥20 % of subjects) were redness, swelling and 
tenderness at the injection site, fever, decreased appetite, irritability, increased sleep, and 
decreased sleep. No imbalance of serious adverse events following vaccination were 
observed when compared to PCV7. The most frequently reported local reaction was 
tenderness, and the most frequently reported systemic adverse event was irritability. In 
the largest U.S. safety study, moderate fever occurred at a statistically significantly 
higher rate in PCV13 recipients compared to PCV7 recipients after the second dose. This 
finding was not observed in smaller studies. Across all studies, four subjects died due to 
sudden infant death syndrome-SIDS (3 received PCV13). There were no consistent trends 
identified (FDA. Vaccines: approved products. PCV13).  
 
The severity of local and systemic reactions after vaccination with PCV13 and PCV7 
were alike. Thus, the data suggest that the safety profiles of PCV13 and PCV7 were 
comparable in pre-licensure studies (MMWR March 12, 2010 / 59(09);258-261), 
suggesting that the safety profile of licensed PCV13 will be similar to that of PCV7 
vaccine. 
 
1.2 Purpose of Study 
 
This investigation aimed to assess the potential adverse events reported to VAERS 
following immunization with PCV13 in the first year of post-licensure and to compare 
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clinically significant adverse events following receipt of PCV13 with those that have 
been observed after PCV7.   
This study will help to ascertain the safety profile of PCV13, detect potential safety 
signals that might be of public health importance and the need for additional studies for 
clarification and to inform vaccine benefit-risk decision making. 
 
1.3 Research Questions 
 
In order to review the safety profile and investigate the most frequently reported adverse 
events after vaccination with PCV13 the following questions must be addressed: 
 
What are the most common adverse events reported to VAERS following immunization 
with PCV13 during the first year post-licensure? 
 
What are the frequencies when comparing adverse events of PCV13 with PCV7’s safety 
profile? 
 
Are adverse events reported after vaccination with PCV13 the same as those expected 
and listed in the package insert?  
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CHAPTER II 
 
REVIEW OF THE LITERATURE 
 
 
2.1 Pneumococcal Vaccines in the U.S. 
 
Worldwide pneumonia is the most common cause of deaths related to pneumococcal 
disease. The World Health Organization estimates that approximately 1.9 million 
children die each year as a result of an acute respiratory infection, mainly pneumonia. 
(Mulholland K et al., 2003) although this might be an underestimate since the majority of 
the childhood deaths occur at home without autopsy. The introduction of new and better 
vaccines to protect against pneumococcal disease can have considerable impact in 
reducing mortality.  
 
The first pneumococcal vaccine trials began in 1911. The first pneumococcal vaccine was 
licensed in the United States in 1977 and included 14 serotypes. In 1983, a 23-valent 
pneumococcal polysaccharide vaccine (PPSV23) was licensed and replaced the 14-valent 
vaccine.  It was recommended for all patients 65 years of age or older and for children 2 
years of age or older. However, PPSV23 vaccine immunogenicity was insufficient owing 
to a lack of a good T-cell independent immune response and the vaccine was therefore 
was less effective in preventing pneumococcal disease in children. A 7-valent conjugate 
pneumococcal vaccine (PCV7, Prevnar®) was licensed in the U.S in 2000, using capsular 
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polysaccharides from selected serotypes conjugated to a protein carrier to stimulate a T-
cell dependent immune response.  PCV7 induces both a systemic and mucosal immune 
response to prevent nasopharyngeal colonization by bacteria (Edwards et al., 2003). 
Ninety pneumococcal serotypes have been identified.   It is estimated that about 62% of 
invasive disease worldwide is caused by the 10 most common serotypes (Atkinson et al., 
2009). In 2010 the 13-valent pneumococcal vaccine (PCV13, Prevnar 13®) was licensed 
in the U.S covering for thirteen serotypes including those in PCV7 vaccine and six 
additional serotypes (Table 1).  
 
Table 1. Pneumococcal Vaccines Licensed for Immunization and Distribution in the U.S. 
Vaccine  Trade name Manufactur
er 
Year 
Licensed  
Age group 
Pneumovax 23 - 
Pneumococcal 
Vaccine, Polyvalent  
Pneumovax 
23®  
Merck & 
Co, Inc  
1983 All adults aged ≥65 
years and those adults 
aged 19--64 years with 
underlying medical 
conditions that put them 
at greater risk for serious 
pneumococcal infection 
Pneumococcal 7-
valent Conjugate 
Vaccine (Diphtheria 
CRM197 Protein)  
 Prevnar® Wyeth 
Pharm. Inc 
2000 >2 months, ACIP also 
recommends  children 
aged 24--59 months who 
are either unvaccinated 
or who have a lapse in 
PCV7 administration 
Pneumococcal 13-
valent Conjugate 
Vaccine (Diphtheria 
CRM197 Protein)  
 Prevnar 13® Wyeth 
Pharm. Inc 
(acquired 
by Pfizer 
Inc, 2010) 
2010 All children aged 2--59 
months. ACIP also 
recommends PCV13 for 
children aged 60--71 
months with underlying 
medical conditions that 
increase their risk for 
pneumococcal disease or 
complications 
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2.2 Pneumococcal vaccines safety studies  
 
There are currently several studies and clinical trials of pneumococcal conjugated 
vaccines that provide information on vaccine safety. Furthermore, post-marketing 
surveillance for PCV13 is in progress.  
 
The safety of pneumococcal vaccines was established in pre-and post-licensure clinical 
trials in different countries. In a clinical trial conducted in South Africa, a 9-valent 
pneumococcal conjugate vaccine (PCV9) was administered to approximately 20,000 
children with high prevalence of human immunodeficiency virus (HIV). Investigators 
reported viral pneumonia being more frequent in children who received the PCV9 
vaccine than in children who received placebo; in addition, asthma was found to be more 
frequent in PCV9 recipients than in placebo recipients (Klugman et al., 2003). However 
in a study of PCV9 conducted in Gambia, asthma was not a frequently reported adverse 
event following vaccination (Cutts et al., 2005). In the U.S. the most comprehensive 
evaluation of PCV7 during pre-licensure was conducted at Northern California Kaiser 
Permanente (NCKP).  Adverse events reported after vaccination occurred less frequently 
compared to studies previously done in Africa, and asthma was not associated with PCV7 
(FDA. Product approval information –CBER, 2010). In the first two years post-licensure 
of PCV7, adverse events reported to VAERS in patients less than 18 years old after 
immunization with PCV7 were minor and similar to those occurring in pre-licensure 
clinical trials (Wise et al., 2004). In a systematic review of 42 studies regarding PCV7 
safety profile in several industrialized and developing countries, investigators did not 
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identify major safety problems with pneumococcal vaccines (DeStefano et al., 2008). 
None of the previous studies found increased risk of death following immunization with 
pneumococcal conjugated vaccine and no major safety problems were identified. The 
World Health Organization recommended incorporating pneumococcal conjugate vaccine 
to all immunization programs (WHO, 2007) 
 
Since the introduction of PCV7 vaccination, invasive pneumococcal disease (IPD) has 
decreased in children less than 5 years (Whitney et al., 2006) although an small increase 
(about 5 per 100,000) of IPD in the general population was detected and was determined 
to be caused by serotype 19A not included in PCV7 vaccine. However since 2002 the 
overall rates of IPD have level off to approximate 22-25 cases per 100,000 in children 
less than 5 years old (Pilishvili et al., 2010).   
 
2.3 Monitoring Vaccine Safety  
 
The National Childhood Vaccine Injury Act (NCVIA) of 1986 was enacted to manage 
the claims of people that reported adverse events or death after immunizations, and thus 
help to take care of financial liabilities as well as supervise market supply.  The act 
required health professionals and vaccine manufacturers to report to the U.S. Department 
of Health and Human Services specific adverse events that occur after the administration 
of routinely recommended vaccines (National Childhood Vaccine Injury Act of the 
Public Health Service).  
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The Centers for Disease Control and Prevention (CDC) has vaccine safety post licensure 
monitoring systems in place to detect and respond to a potential adverse events following 
immunization. 
 
VAERS is a national passive surveillance system and is operated by the CDC and the 
Food and Drug Administration (FDA) to accept reports from health care providers, 
vaccine manufacturers, the public and others on possible adverse events following 
immunization. 
 
2.4 The Vaccine Adverse Events Reporting System (VAERS) 
 
The Vaccine Adverse Events Reporting System (VAERS) is a passive reporting system 
used to monitor vaccine safety. It was established in 1990 and is jointly administered by 
the Centers for Disease Control and Prevention (CDC) and the Food and Drug 
Administration (FDA). VAERS accepts reports of adverse events after vaccination from 
vaccine manufacturers, healthcare providers, vaccine recipients, and others. VAERS 
generally cannot assess whether a vaccination caused an adverse event, but can identify 
possible vaccine safety problems for further investigation (Varricchio F et al., 2004). 
 
VAERS is the largest United States post-licensure surveillance system and has provided 
useful information on the safety profile of pneumococcal vaccines in the general 
population of children and adults. Because of its size and national scope, VAERS can 
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provide information on rare adverse events that may not be detected in pre-licensure 
clinical trials.  
 
VAERS serves as the U.S. “early warning” system for potential vaccine safety concerns 
(signal detection) about adverse events and reported frequencies compared to what would 
be expected to be associated with the use of an specific product (Table 2). 
 
Table 2. Signal Detection  
 
 
VAERS uses the Medical Dictionary for Regulatory Activities (MedDRA) to code the 
signs and symptoms about reported adverse events on each report (MedDRA 
Maintenance and Support Service Organization). Reports may have multiple MedDRA 
codes and might include simultaneous vaccinations.  
Reports are classified as serious, based on the Code of Federal Regulations (FDA, 21CFR 
314.80) if they result in death, life-threatening illness, hospitalization or prolongation of 
hospitalization, permanent disability, or if a congenital anomaly is reported (FDA., 
Postmarketing reporting of adverse experiences; 1997). All serious events are reviewed. 
Data 
Source Strengths Limitations 
VAERS Nationwide  Underreporting  
  
Near real-time  Consistency  
  
Detection of rare or unexpected events  Variable quality of reported information  
  
Lot specific surveillance  Specifics on vaccines used  
  
Data mining Variable reporting biases  
  
  Poorly defined denominators  
  
  No controls 
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This regulatory definition of a serious report does not always reflect the severity of an 
outcome. Reports are usually submitted by electronic mail by accessing 
http://www.vaers.org, regular mail or fax. All serious adverse events and deaths are 
followed up by FDA and CDC medical officers and epidemiologists.   
 
2.5 Recommendations for 13-Valent Pneumococcal Conjugate vaccine 
 
PCV13  is part of the U.S recommended immunization schedule for persons aged 0 
through 6 years (Figure 1). PCV13  is approved for use among children aged 6 weeks--71 
months and recommended as a four dose series at ages 2, 4, 6, and 12-15 months. PCV13 
will succeed PCV7. On February 24, 2010, PCV13 was recommended (MMWR 
December 10, 2010 / 59(RR11);1-18) by the Advisory Committee on Immunization 
Practices (ACIP) for routine vaccination of:  
• All children aged 2--59 months (Appendix A: Tables 3, 4 and 5). 
• Children aged 60--71 months with underlying medical conditions that increase their 
risk for pneumococcal disease or complications (Appendix A: Table 6). 
• Children who previously received 1 or more doses of PCV7.  
• Unvaccinated children and children incompletely vaccinated with PCV7-- Transition 
from PCV7 to the PCV13 immunization program (Appendix A: Table 7) 
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Chapter III 
 
METHODOLOGY 
 
3.1 Data Source 
 
We searched and reviewed reports of adverse events after PCV13 submitted to  the 
Vaccine Adverse Event Reporting System (VAERS).  
We searched for reports received by February 24, 2011 for persons vaccinated with 
PCV13 from February 24, 2010 through December 31, 2010. In order to assess the 
reporting trends and whether the proportions of reports received after PCV13 
immunization were similar to PCV7 in previous years we went back avoiding seasonal 
pattern and reviewed safety data, U.S VAERS reports for adverse events reported 
following PCV7 from February 24, 2000 through February 24, 2001, persons vaccinated 
with PCV7 from February 24, 2000 through December 31, 2000. The total number of 
adverse events was stratified for PCV13 and PCV7. The numbers of deaths, non-fatal 
serious and non-serious reports were determined. Non-US reports were excluded.  
We used information from VAERS which included demographics on the recipient (age, 
sex, etc,), type of vaccine, vaccination date, manufacturer, vaccine lot number, doses 
previously received, date of onset of symptoms and description of the event. Onset 
interval is the number of days from the time of vaccination to the onset of earliest 
reported symptoms. 
18 
 
Crude reporting rates for VAERS adverse events per 100,000 doses of vaccine were 
calculated by dividing the number of events occurring within the 12 months after PCV13 
vaccination by total doses of PCV13 vaccine distributed in the United States. To calculate 
reporting rates, distribution data (total doses of PCV13 vaccine distributed) provided by 
vaccine manufacturer were used as an estimate of total doses administered to U.S. and as 
“denominator” to estimate reporting rates.  
 
Based on pre- and post-licensure safety data on pneumococcal conjugate vaccines, 
special attention was paid to respiratory events that followed PCV13 vaccination 
including reactive airway disease and asthma (DeStefano F et al.,2008). A pre-specified 
group of combined MedDRA preferred terms was used as a search criterion to select 
potential asthma and reactive airway disease reports (bronchospasm, wheezing, asthma, 
status asthmaticus, reversible airway obstruction, bronchial hyper reactivity, asthmatic 
crisis, infantile asthma and respiratory distress). 
 
3.2 Statistical Analysis  
 
Descriptive statistics were used to describe the epidemiology of reports submitted to the 
VAERS, a national passive surveillance database for the U.S.   
The VAERS database use standardized coding terms that are assigned after review of 
each report by trained personnel. Most reports receive multiple codes.  
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Because VAERS is a routine surveillance program that does not meet the definition of 
research, it is not subject to Institutional Review Board review and informed consent 
requirements. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
20 
 
Chapter IV 
 
RESULTS 
 
4.1 Frequencies and Descriptive Statistics 
 
From February 24, 2010, through February 24, 2011, VAERS received 1,503 reports of 
adverse events following receipt of PCV13; 180/1,503 or 11.9% reports were described 
as serious including 19 fatalities and most of the reports were described as non-serious 
(1,323/1,503 or 88%). From February 24, 2000, through February 24, 2001, a total of 963 
reports were received after PCV7 vaccination; 114 (11.8%) were serious; including 23 
reports of death, and 849 (88%) reports were non-serious. The number of death reports 
received over the first year after PCV13 licensure (19/1,503 or 1.3%) was less than the 
first post licensure year for the PCV7 group (23/963 or 2.4%). The percentage of serious 
reports after vaccination with PCV13 was lower compared to PCV7 (Table 8).  
 
Among all, the most frequently reported adverse events following immunization were 
injection site erythema (25.5%, 15.2%), pyrexia (24.2%, 32.0%) and injection site 
swelling (19.4%, 5.5%) for PCV13 and PCV7, respectively (Table 9). Other common 
adverse events reported after PCV13 were irritability, injection site pain and vomiting.  
No unexpected serious events or death appeared to be associated with PCV13 or PCV7. 
In the analysis among serious reports, pyrexia (38.9%, 28.9%), irritability (36.1%, 
11.4%) and vomiting (35.6%, 8.8%) were the most frequently reported adverse events for 
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PCV13 and PCV7, respectively (Table 10). The median age (<1 year) were the same for 
PCV13 and PCV7 whereas the median onset interval was 2 and 1 day for PCV13 and 
PCV7 respectively. 
 
The percentage of persons receiving the pneumococcal vaccine alone with no other 
antigens was higher for PCV13 compared to PCV7; In 323 of 1,503 reports (21%) 
PCV13 was the only vaccine administered, the remaining 79% of reports described 
simultaneous vaccination of PCV13 with a variety of other vaccines. Whereas 324 of 963 
reports (34%) noted PCV7 administration without simultaneous vaccinations.  
 
Most of the adverse events reported in both groups happened within one day of 
vaccination. For PCV13, of the 1380 reports that included onset interval, 545 (36%) 
occurred on the day of vaccination compared to PCV7 reports whereas 927 reports 
including onset interval, 347 (36%) occurring the same day of vaccination. The median 
age of recipients reporting adverse events to VAERS after immunization with PCV13 and 
PCV7 was the same (<1 year). 50% (758/1503) and 51% (493/963) of reports received 
were in males for PCV13 and PCV7, respectively; for the PCV13 reports, 48% were in 
females and 1% were reports with unspecified gender whereas for the PCV7, 45% were 
in females and 3% reports had unspecified gender.   
 
There were no significant differences in reporting practices to VAERS by recipients. The 
majority of reports following PCV13 (941/1503, or 63%) were submitted by the 
healthcare provider, compared to 39% reports submitted by providers after vaccination 
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with PCV7. Other additional sources of reporting included manufacturer (7%, 23%), 
patients or parents (4%, 3%), state health clinics (3%, 6%), and “others” (23%, 3%) for 
PCV13 and PCV7, respectively. The proportions of reported adverse events found for all 
reports received after vaccination with PCV13 were lower for calculated age group <6 
months and 6-11 months (22% and 10% vs. 25% and 22%) compared to PCV7; for the 
calculated age group 3-5 years the proportion was greater (29% vs. 8%) compared to 
PCV7. 
 
Table 8. Characteristics of the Vaccine Adverse Event Reporting System (VAERS) U.S. 
reports following receipt of PCV13 vaccine February 24, 2010 through February 24, 
2011 (n=1503) and PCV7 vaccine February 24, 2000 through February 24, 2001 (n=963) 
Characteristic PCV13 PCV7 
All reports n=1503 n=963 
Serious reports 11.9% (180/1503) 11.8% (114/963) 
Deaths 1.2% (19/1503) 2.4% (23/963) 
Recipients age in years a (median [range]) 1.0 (0 – 75.0) 1.0 (0 – 80.0) 
Onset interval in days b (median [range]) 1.0 (0 – 91.0) 1.0 (0 – 204.0) 
Male reports c 50.4% (758/1503) 51.1% (493/963) 
Vaccine given alone 21.0% (323/1503) 33.6% (324/963) 
Reports with MedDRA d term coded for 
“wheezing” 2.1 % (31/1503) 0.7% (7/963) 
Reports with MedDRA d term coded for 
“asthma” e 2.4 % (36/1503) 0.9 % (9/963) 
Age group   
< 6 mos 21.6% (325/1503) 25.3% (244/963) 
6-11 mos 9.5% (143/1503) 22.1% (213/963) 
1-2 years 37.7% (567/1503) 41.3% (398/963) 
3-5 years 28.8% (433/1503) 7.6% (74/963) 
>=6 years 0.68% (11/1503) 1.8% (18/963) 
Unknown 1.6% (25/1503) 1.6% (16/963) 
 
a
 Age unknown for 25 and 16 reports for PCV13 and PCV7 respectively.  
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b
 Onset unknown for 123 and 36 reports for PCV13 and PCV7 respectively. Days from 
the time of vaccination to the onset of the earliest reported symptoms. 
c
 Gender unknown for 21 and 32 reports for PCV13 and PCV7 respectively.    
d
 The Medical Dictionary for Regulatory Activities (MedDRA) was used to code 
symptoms and/or conditions described in each report.  
e
 Asthma Combined MedDRA PTs:  Bronchospasm, wheezing, asthma, status 
asthmaticus, reversible airway obstruction, bronchial hyperreactivity, asthmatic crisis, 
infantile asthma, respiratory distress.  
 
Table 9. Most common reported frequencies of adverse events occurring after 
vaccination with PCV13 (PCV13) and PCV7 (Prevnar®); ALL reports. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reported frequencies of adverse events occurring following 
administration of PCV13 and PCV7—All reports 
% Adverse event PCV 13* PCV 7† 
  (n = 1,503) (n = 963) 
Injection site erythema 25.5 15.2 
Pyrexia 24.2 32.0 
Injection site swelling 19.4 5.5 
irritability 10.3 11.1 
Injection site pain 9.8 5.5 
Injection site warmth 9.8 3.5 
Vomiting 9.2 6.7 
Urticaria 7.5 10.0 
Crying 7.4 3.7 
Erythema 6.5 3.7 
Rash 6.3 8.7 
Body temperature increased 5.8 -- 
Injection site duration 5.2 2.9 
Abbreviations: PCV13 = 13-valent pneumococcal polysaccharide-
protein conjugate vaccine, PCV7 = 7-valent pneumococcal 
polysaccharide-protein conjugate vaccine, and NA = data not available. 
* ALL VAERS reports received following PCV13 immunization 
2/24/10 through 2/24/11; vaccination date 2/24/10 through 12/31/10.  
† ALL VAERS reports received following PCV7 immunization 2/24/00 
through 2/24/01; vaccination date 2/24/00 through 12/31/00.  
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Table 10. Most common reported frequencies of Serious adverse events occurring after 
vaccination with PCV13 (PCV13) and PCV7 (Prevnar®) 
 
Reported frequencies of adverse events occurring following administration of PCV13 
and PCV7—Serious reports 
 
PCV 13*  (n=180) % PCV 7† (n=114) % 
Adverse Event   Adverse Event   
PYREXIA 38.9 PYREXIA 28.9 
IRRITABILITY 36.1 CONVULSION 20.2 
VOMITING 35.6 APNOEA 12.3 
BLOOD CULTURE NEGATIVE 22.8 IRRITABILITY 11.4 
CONVULSION 20.6 LETHARGY 10.5 
INTUSSUSCEPTION 19.4 CYANOSIS 9.6 
DIARRHOEA 18.9 VOMITING 8.8 
UNRESPONSIVE TO STIMULI 16.1 ANOREXIA 8.8 
COUGH 16.1 SUDDEN INFANT DEATH SYNDROME 8.8 
PLATELET COUNT INCREASED 15.6 COMA 7 
ULTRASOUND ABDOMEN ABNORMAL 15.6 BACTERIAL INFECTION 7 
CRYING 15.6 HYPOTONIA 7 
WHITE BLOOD CELL COUNT INCREASED 13.9 PNEUMONIA 7 
ENEMA ADMINISTRATION 12.8 FEBRILE CONVULSION 5.3 
CULTURE URINE NEGATIVE 12.8 SOMNOLENCE 5.3 
LYMPHOCYTE PERCENTAGE 
DECREASED 12.2 
PALLOR 5.3 
SOMNOLENCE 12.2 RASH 5.3 
HAEMATOCRIT DECREASED 12.2 LABORATORY TEST ABNORMAL 4.4 
CHEST X-RAY ABNORMAL 12.2 CARDIAC ARREST 4.4 
ELECTROENCEPHALOGRAM NORMAL 12.2 UPPER RESPIRATORY TRACT INFECTION 3.5 
GAZE PALSY 12.2 DEHYDRATION 3.5 
CHEST X-RAY NORMAL 12.2 AGITATION 3.5 
HAEMATOCHEZIA 11.7 UNEVALUABLE EVENT 3.5 
NEUTROPHIL PERCENTAGE INCREASED 11.7 STUPOR 3.5 
COMPUTERISED TOMOGRAM NORMAL 11.7 STARING 3.5 
Abbreviations: PCV13=13-valent pneumococcal polysaccharide-protein conjugate 
vaccine, PCV7= 7-valent pneumococcal polysaccharide-protein conjugate vaccine. 
25 
 
* Serious VAERS reports received following PCV13 immunization 2/24/10 through 
2/24/11; vaccination date 2/24/10 through 12/31/10. 
† Serious VAERS reports received following PCV7 immunization 2/24/00 through 
2/24/01; vaccination date 2/24/00 through 12/31/00. 
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Chapter V 
 
DISCUSSION AND CONCLUSION 
 
5.1 Discussion 
 
In the pre-licensure safety database, which includes approximately 15,000 doses and 
5,000 recipients, no safety signals were identified. The available post-marketing data 
support an acceptable safety profile for PCV13. The great majority of reports in the first 
year after PCV13 licensure described minor signs and symptoms previously documented 
during clinical trials. The proportion of reports describing serious events (11.9%) was 
similar to that reported on a regular basis for other vaccines in the data system (14.3%) 
(Zhou W, et al. 2003). Nonetheless, further investigation for unusual reports of serious 
events (i.e. seizures), including requesting medical records for clinical review and follow 
up, continues to be a priority.   
 
Although the total number of VAERS reports received following PCV13 vaccination was 
higher than the total reports received following PCV7 vaccination for all age groups in 
the previous year, the findings must be carefully interpreted since enhanced reporting to 
VAERS has been documented when a new vaccine is licensed and available to the public. 
In addition, an increase in adverse events that may attributable in part to heightened 
public perception and awareness (Zhou W et al., 2003). Finally, each VAERS report 
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usually includes multiple MedDRA codes and occasional duplicate coding or coding 
errors may appear, also many reported events may not be due to the vaccine. 
 
Asthma and reactive airway disease have been found statistically important in previous 
pneumococcal studies (Klugman et al., 2003). This investigation looked for asthma and 
reactive airway disease reports using pre-specified MedDRA codes and demonstrated no 
difference in proportional reporting after PCV13 vaccination compared with PCV7 
vaccine. Local reactions are very common after vaccination of any type and very often 
occur with minor symptoms and with no sequelae. Expected reports of pyrexia as a 
frequent adverse event were observed, however findings were similar in both groups and 
similar to previous studies of these vaccines. Fever is also a common symptom in 
children and not necessarily related to vaccination.  
 
 
5.2 Study Limitations 
 
VAERS is a passive surveillance system with limitations that include both under-
reporting and biased reporting that can affect the outcome and analysis.   More important, 
VAERS generally does not assess causality. Because VAERS accepts reports from any 
person, it is common to find duplicates or errors in reporting as well as missing data (i.e. 
demographics) in some cases. However VAERS has been used as an important 
surveillance tool and demonstrated to be very helpful when assessing vaccine safety 
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(MMWR February 6, 2009 / 58(RR02);1-25) and has a national capacity that permitted 
us to investigate in a large and diverse population. 
  
This study assessed associations between adverse event reported to VAERS after 
vaccination with PCV13, however for a stricter and deeper analysis of direct associations 
of vaccination and adverse events an exhaustive clinical review of each serious report 
will be necessary to rule out similar reported clinical symptoms and signs  in order to be 
able to establish cases and their association with safety concerns.  Another limitation was 
the inability to calculate adjusted reporting rates for selected adverse events.  
 
 
5.3 Recommendations 
 
1. More surveillance and multidisciplinary approaches are needed to address the 
limitations of VAERS. Clinical review of medical records would help to understand 
better the nature of the adverse events reported.  
 
2. Health professionals, health care providers and policy makers must develop and 
implement interventions to spread the knowledge to the general public regarding the 
safety of the vaccines as well as let people know about systems that are in place for 
continue monitoring vaccine safety issues in addition to insist in the benefits of and 
the need for immunizations against vaccine preventable diseases. 
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3. Encourage all healthcare personnel and public in general to use the VAERS system to 
report any clinically significant medical event that occurs after vaccination,  even if 
the reporter cannot be sure that the event was caused by the vaccine. If no minor 
adverse event is unreported, the better the data captured and the higher the probability 
for a correct assessment, increasing the availability of information and continued 
monitoring of the safety of the PCV13 are key for ensuring optimal public health 
decisions and public confidence in the Pneumococcal 13-valent Conjugate Vaccine.  
  
 
5.4 Conclusion 
 
We were able to compare PCV13 and PCV7 risk profile. Among all reports, frequencies 
of solicited adverse events after vaccination with PCV13 were similar to those reported in 
prior studies and those currently listed in the package insert. No unexpected adverse 
events reported after PCV13 vaccination. 
 
The safety profile of the PCV13 needs to be considered in the context of the benefits of 
vaccination, which includes the disease epidemiology and the vaccine effectiveness. 
Education about the recommendations, safety and importance of immunization with 
pneumococcal vaccines is fundamental to decrease disease rates.  
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APPENDIX A: Recommended schedule for use of PCV13  
 
Table 3. Recommended schedule for use of 13-valent pneumococcal conjugate vaccine 
 
Recommended schedule for use of 13-valent pneumococcal conjugate vaccine (PCV13) among 
previously unvaccinated infants and children by age at time of first vaccination 
Age at first dose (mos) Primary PCV13 
series*  PCV13 booster dose† 
2--6 3 doses 1 dose at 12--15 mos 
7--11 2 doses 1 dose at 12--15 mos 
12--23 2 doses NA 
24--59 in healthy children 1 dose NA 
24--71 in children with certain chronic 
diseases or immunocompromising conditions§ 
2 doses NA 
Abbreviation: NA = not applicable 
* Minimum interval between doses is 8 weeks except for children vaccinated at age <12 months, 
for whom minimum interval between doses is 4 weeks. Minimum age for administration of first 
dose is 6 weeks. 
† Administered at least 8 weeks after the previous dose. 
§ See Table 6 for a complete list of conditions. 
 
 
Table 4. Recommended schedule for use of 13-valent pneumococcal conjugate vaccine 
 
 
Recommended schedule for administering doses of 13-valent pneumococcal conjugate vaccine 
(PCV13) to children aged <24 months by PCV vaccination history and age --- Advisory 
Committee on Immunization Practices, US, 2010 
Age at this visit 
(mos) 
Vaccination history: total 
number of PCV7 and/or 
PCV13 doses received 
previously 
Recommended PCV13 regimen* 
0 doses 3 doses, 8 weeks apart; fourth dose at 
age 12--15 mos 
1 dose 2 doses, 8 weeks apart; fourth dose at 
age 12--15 mos 
2--6 mos 
2 doses 1 dose, 8 weeks after the most recent 
dose; fourth dose at age 12--15 mos 
0 doses 2 doses, 8 weeks apart; third dose at 12--
15 mos 
7--11 mos 
1 or 2 doses before age 7 mos 1 dose at age 7--11 mos, with a second 
dose at 12--15 mos, ≥8 weeks later 
12--23 mos 0 doses 2 doses, ≥8 weeks apart 
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  1 dose before age 12 mos 2 doses, ≥8 weeks apart 
  1 dose at ≥12 mos 1 dose, ≥8 weeks after the most recent 
dose† 
  2 or 3 doses before age 12 
mos 
1 dose,≥8 weeks after the most recent 
dose† 
  4 doses of PCV7 or other age-
appropriate, complete PCV7 
schedule 
1 supplemental dose ≥8 weeks after the 
most recent dose 
Abbreviation: PCV7 = 7-valent pneumococcal polysaccharide-protein conjugate vaccine. 
* Minimum interval between doses is 8 weeks except for children vaccinated at age <1 year, for 
whom minimum interval between doses is 4 weeks. 
† No additional PCV13 doses are indicated for children aged 12--23 months who have received 
2 or 3 doses of PCV7 before age 12 months and at least 1 dose of PCV13 at age ≥12 months. 
 
Table 5. Recommended schedule for use of 13-valent pneumococcal conjugate vaccine 
 
Recommended schedule for administering doses of 13-valent pneumococcal conjugate vaccine 
(PCV13) to children aged ≥24 months by PCV vaccination history and age  
Age at this visit 
(mos) 
Vaccination history: total 
number of PCV7 and/or 
PCV13 doses received 
previously before age 24 
months 
Recommended PCV13 regimen* 
24--59 mos in 
healthy children 
Unvaccinated or any 
incomplete schedule 
1 dose, ≥ 8 weeks after the most recent dose 
  4 doses of PCV7 or other 
age-appropriate, complete 
PCV7 schedule 
1 supplemental dose, ≥8 weeks after the most 
recent dose 
24--71 mos in 
children with 
underlying 
medical 
conditions† 
Unvaccinated or any 
incomplete schedule of <3 
doses 
2 doses, the first dose ≥8 weeks after the most 
recent dose and a second dose ≥ 8 weeks later 
  Any incomplete schedule of 
3 doses 
1 dose, ≥ 8 weeks after the most recent dose 
  4 doses of PCV7 or other 
age-appropriate complete 
PCV7 schedule 
1 supplemental dose, ≥8 weeks after the most 
recent dose 
Abbreviation: PCV7 = 7-valent pneumococcal polysaccharide-protein conjugate vaccine. 
* Minimum interval between doses is 8 weeks. 
† For list of conditions, see Table 6. 
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Table 6.  Underlying medical conditions that are indications for pneumococcal 
vaccination 
Underlying medical conditions that are indications for pneumococcal vaccination among 
children, by risk group --- Advisory Committee on Immunization Practices (ACIP), United 
States, 2010 
Risk group Condition 
Chronic heart disease* 
Chronic lung disease† 
Diabetes mellitus  
Cerebrospinal fluid leaks 
Immunocompetent 
children 
Cochlear implant 
Sickle cell disease and other hemoglobinopathies Children with functional or 
anatomic asplenia Congenital or acquired asplenia, or splenic dysfunction 
HIV infection 
Chronic renal failure and nephrotic syndrome 
Diseases associated with treatment with immunosuppressive drugs 
or radiation therapy, including malignant neoplasms, leukemias, 
lymphomas, and Hodgkin disease; or solid organ transplantation 
Children with 
immunocompromising 
conditions 
Congenital immunodeficiency§  
* Particularly cyanotic congenital heart disease and cardiac failure. 
† Including asthma if treated with prolonged high-dose oral corticosteroids.  
§ Includes B- (humoral) or T-lymphocyte deficiency; complement deficiencies, particularly C1, 
C2, C3, and C4 deficiency; and phagocytic disorders (excluding chronic granulomatous disease). 
 
Table 7. Recommended transition schedule 
Recommended transition schedule from 7-valent pneumococcal conjugate vaccine (PCV7) to 
13-valent vaccine (PCV13) vaccination among infants and children, according to number of 
previous PCV7 doses received --- Advisory Committee on Immunization Practices (ACIP), 
United States, 2010 
Supplemental Infant series Booster 
dose PCV13 dose 
2 mos 4 mos 6 mos ≥12 mos* 14--59 mos† 
PCV7 PCV13 PCV13 PCV13 --- 
PCV7 PCV7 PCV13 PCV13 --- 
PCV7 PCV7 PCV7 PCV13 --- 
PCV7 PCV7 PCV7 PCV7 PCV13 
* No additional PCV13 doses are indicated for children age 12--23 months who have received 2 
or 3 doses of PCV before age 12 months and at least 1 dose of PCV13 at age ≥12 months. 
† For children with underlying medical conditions (see Table 6), a single supplemental PCV13 
dose is recommended through age 71 months  
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FIGURE 1: Recommended immunization schedule for persons aged 0 through 6 
years, U.S, 2011 
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